

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

Please cancel claims 3, 4, 8, 10, 12-20 and 26.

Please amend claims 1, 2, 5, 7, 11 and 21 as follows:

LISTING OF CLAIMS:

1. (CURRENTLY AMENDED) A medical device comprising a site-specific delivery device for the controlled release of at least one peroxisome proliferator-activated receptor gamma (PPAR γ) agonist.

2. (CURRENTLY AMENDED) The medical device according to claim 1 wherein said PPAR γ agonist is ~~a thiazolidinedione~~ rosiglitazone.

3. (CANCELED)

4. (CANCELED)

5. (CURRENTLY AMENDED) The medical device according to any of claims 1, or 2, 3 or 4 wherein said medical device is ~~a selected from the group consisting of stents, catheters, micro-particles, probes and vascular grafts.~~

6. (ORIGINAL) The medical device according to claim 5 wherein said stent is a vascular stent or biliary stent.

7. (CURRENTLY AMENDED) The medical device according to claim 6 wherein said vascular stent is provided with a coating comprising rosiglitazone ~~at least one thiazolidinedione~~.

8. (CANCELED)

9. (ORIGINAL) The medical device according to claim 8 wherein said coating further contains a biocompatible polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

10. (CANCELED)

11. (CURRENTLY AMENDED) A medical device comprising a stent having a coating comprising rosiglitazone ~~at least one thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof~~; and
a polymer selected from the group consisting of polyvinyl pyrrolidone, polytetrafluoroethylene, poly-L-lactic acid, polycaprolactone, polyethylene glycol, polystyrene, acrylates, polyesters and mixtures thereof.

Claims 12 - 20. (CANCELED)

21. (CURRENTLY AMENDED) A medical device comprising a stent having a coating comprising rosiglitazone ~~at least one thiazolidinedione selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, darglitazone, englitazone, ciglitazone, derivatives thereof and combinations thereof~~; and
at least one additional therapeutic agent selected from the group consisting of antiplatelet agents, antimigratory agent, antifibrotic agents, antiproliferatives, antiinflammatories and combinations thereof providing that said additional therapeutic agent is not a PPAR γ agonist.

22. (ORIGINAL) The medical device according to claim 21 wherein said at least one additional therapeutic agent is selected from the group consisting of antisense oligonucleotides, rapamycin, analogues of rapamycin, exochelin, n-acetyl cysteine inhibitors, chaperone inhibitors and combinations thereof.

23. (ORIGINAL) The medical device according to claim 22 wherein said antisense oligonucleotide is an anti-c-myc oligonucleotide.

24. (ORIGINAL) The medical device according to claim 22 wherein said chaperone inhibitor is geldanamycin.

25. (ORIGINAL) The medical device according to claim 22 wherein said rapamycin derivative is 40-0-(2-hydroxyethyl)-rapamycin.

26. (CANCELED)